Last reviewed · How we verify
Occipital Nerve Block
An occipital nerve block is a local anesthetic injection that temporarily numbs the occipital nerves to relieve pain in the back of the head and neck.
Occipital Nerve Block (ONB) is a procedural intervention—not a traditional pharmaceutical drug—administered by University of Alabama at Birmingham and other academic medical centers for management of headache disorders including migraine, post-traumatic headache, and occipital neuralgia. The procedure involves injection of local anesthetic (typically lidocaine or bupivacaine) with or without corticosteroids around the greater occipital nerve at the base of the skull, providing rapid symptom relief through local anesthetic blockade and potential anti-inflammatory effects. Currently in clinical use with 50 registered trials spanning Phase 1–4 and observational studies, ONB demonstrates efficacy across acute migraine, episodic migraine, chronic migraine, post-operative pain, and medication-overuse headache, with particular strength in pregnancy-related headache where systemic alternatives are contraindicated. Clinical differentiation centers on non-systemic delivery, rapid onset, and safety profile in vulnerable populations; competitive positioning against oral triptans, CGRP antagonists, and other interventional procedures remains evolving. Commercial significance is limited by procedural nature and lack of branded pharmaceutical revenue; reimbursement varies by payer and geography. Pipeline expansion includes ultrasound-guided techniques, radiofrequency ablation variants, and application to spontaneous intracranial hypotension.
At a glance
| Generic name | Occipital Nerve Block |
|---|---|
| Also known as | Acetaminophen/Caffeine |
| Sponsor | University of Alabama at Birmingham |
| Drug class | Local anesthetic nerve block procedure |
| Modality | Small molecule |
| Therapeutic area | Neurology / Pain Management |
| Phase | FDA-approved |
Mechanism of action
The procedure involves injecting local anesthetic (typically lidocaine or bupivacaine) around the greater and/or lesser occipital nerves at the base of the skull. This blocks pain signal transmission from the occipital nerve distribution, providing temporary relief of occipital neuralgia and related headache conditions. The effect is reversible and typically lasts from days to weeks depending on the anesthetic used.
Approved indications
- Occipital neuralgia
- Migraine headaches
- Tension-type headaches
- Cervicogenic headaches
Common side effects
- Temporary numbness or tingling at injection site
- Mild pain at injection site
- Temporary dizziness
- Infection (rare)
- Nerve injury (rare)
Key clinical trials
- Effect of Scalp Block on Intraoperative Hemodynamics and Postoperative Pain in Craniotomy Patients" (NA)
- Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache (NA)
- Treatment Response in Patients With Medication-Overuse Headache
- Efficacy of Nerve Blocks for Episodic Migraine (PHASE2)
- Greater Occipital Nerve Pulsed Radiofrequency in Cervicogenic Headache (NA)
- Comparison of Systemic Opioid (Morphine) and Pre-Incision Bilateral Scalp Nerve Block for Pain Management in Craniotomy Patients (PHASE4)
- Treatment Response to GON Pulsed Radiofrequency in Elderly Patients With Chronic Migraine
- The Effect of Interventional Procedures on Serum CGRP and PACAP-38 Levels in Chronic Migraine (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Occipital Nerve Block CI brief — competitive landscape report
- Occipital Nerve Block updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI